Genknowme

What Genknowme does

Genknowme is a Swiss precision-health company founded in 2019 in Lausanne that develops and commercializes epigenetic tests delivered through healthcare professionals. Its product portfolio centers on the Biological Age & Lifestyle Profile and the Epigenetic Stress Profile, with the Epigenetic Longevity Index (ELI) in development. The technical stack uses Illumina Infinium MethylationEPIC v2.0 BeadChips to measure DNA methylation at scale, processed through proprietary statistical algorithms validated against the Swiss SKIPOGH cohort (1,000+ participants). A patent application for biological age assessment was filed in March 2022, and the chronic-stress biomarker work has been published in Bioscience Reports (March 2025).

The business operates a B2B model: tests are ordered by clinicians and institutional partners rather than sold direct-to-consumer. Distribution runs through premium Swiss clinics (Clinique La Prairie, Hôpital de la Tour), wellness providers (Therme Zurzach), and academic partners (CHUV, Unisanté). The company holds authorization from the Swiss Federal Office of Public Health (FOPH) — described as the only such facility authorized for sensitive-trait genetic/epigenetic analyses in Switzerland — and is GDPR-compliant. In 2025 the company secured reimbursement from a major Swiss health insurer, introducing a third-party-payer revenue layer to a model previously funded through out-of-pocket clinical sales.

Capitalization to date combines non-dilutive grants (VentureKick stages in 2019–2020, CHF 100K FIT in 2020) with equity rounds in 2025 (CHF 500K plus additional disclosed tranches), with stated use of proceeds directed at market expansion and insurance reimbursement integration. Founding leadership comprises Dr. Semira Gonseth Nusslé (CMO) and Sébastien Nusslé, PhD (CEO & CSO). The team remains in the 1–10 employee range, consistent with a company still building commercial scale on top of a validated scientific platform.

Name

Genknowme

Legal name

genknowme SA

Website

https://genknowme.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Genknowme is a Lausanne-based precision-health company (founded 2019) that develops epigenetic tests — Biological Age, Stress Profile, and the in-development Epigenetic Longevity Index — delivered B2B through Swiss clinics, hospitals, and wellness providers, with FOPH authorization and partial Swiss insurance reimbursement.

Ownership category

akta.pro rank

Product category

Epigenetic Diagnostic Testing

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Epigenomics & Chromatin Profiling Services (HLAGANAF)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• Epigenetic diagnostic testing
• Biological age testing
• DNA methylation analysis
• Precision health services
• Clinical laboratory services

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Epigenetic Testing Services: Blood tests for biological age and stress assessment sold to healthcare professionals who order tests for their patients. Tests are performed in Genknowme's Swiss laboratory and results are delivered to prescribing physicians for clinical interpretation.
2. Laboratory Analysis Services: Epigenome-wide DNA methylation analysis services provided to academic laboratories, clinical research units, and industrial R&D departments. Includes delivery of IDAT files or pre-processed data with optional bioinformatic support.
3. Insurance Reimbursement: Growing adoption by Swiss health insurers with recent official reimbursement from a major insurer, providing additional revenue stream through health insurance coverage of tests.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Genknowme provides blood-based epigenetic diagnostic tests — a Biological Age & Lifestyle Profile and an Epigenetic Stress Profile — that quantify DNA methylation biomarkers using Illumina EPIC BeadChips and proprietary algorithms, sold exclusively through licensed healthcare professionals. A complementary Laboratory Analysis Service offers genome-wide methylation profiling for research clients, and a digital client portal with integrated e-commerce supports ordering and result delivery.

Product overview

Genknowme offers a portfolio of epigenetic testing products and laboratory services focused on personalized health assessment. The core offering consists of two blood-based diagnostic tests: the Biological Age & Lifestyle Profile, which measures biological age and lifestyle factor impacts on DNA methylation, and the Epigenetic Stress Profile, which assesses chronic stress effects across cardiovascular, immune, metabolic, and neuroendocrine systems. Both tests work exclusively through healthcare professionals and provide personalized reports with actionable recommendations. The company also offers laboratory analysis services using Illumina Infinium MethylationEPIC v2.0 BeadChips technology. The Epigenetic Longevity Index (ELI), currently under development, will serve as a unified framework combining biological age and allostatic load measurements.

Differentiator

Problem solved

Functional benefit

Brands

• Epigenetic Longevity Index (ELI): A groundbreaking scientific framework under development designed to measure biological age, allostatic load, and essential epigenetic markers to empower individuals to understand, anticipate, and optimize their health and longevity over time.

Products and services

• Biological Age & Lifestyle Profile Blood-based epigenetic test that quantifies a patient's biological age using DNA methylation analysis with the proprietary Swiss Epigenetic Clock and provides a Lifestyle Profile report. Sold exclusively through licensed physicians, clinics, and wellness centers who order it for their patients.
• Epigenetic Stress Profile Blood-based epigenetic test that measures a proprietary allostatic load marker from DNA methylation to assess chronic stress, delivered as a clinician-ready report. Sold exclusively through licensed healthcare professionals for use in patient consultations.
• Laboratory Analysis Service Service that processes DNA samples sent by research and academic clients using Illumina Infinium MethylationEPIC v2.0 BeadChips, bisulfite conversion, and iScan/GenomeStudio to deliver genome-wide DNA methylation data. Targeted at principal investigators and R&D teams that require high-quality methylation profiling without running the wet lab and bioinformatics in-house.

Quantifiable outcome

• Fastest turnaround time worldwide for epigenetic testing (following week delivery)
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Buchinger WilhelmiminorStrategic or Co-development Partner · 24 June 2026Contributed high-quality DNA methylation profiles to research on epigenetic clocks and long-term fasting conducted at Buchinger Wilhelmi, led by Siyuan Luo under supervision of Ferdinand von Meyenn at ETH Zürich.
• Kickstart InnovationminorGTM or Marketing Partner · 9 September 2025Selected as one of 36 scaleups joining the 2025 program. Enables collaboration with 200+ partners across Finance & Insurance, Health & Wellbeing, Smart Cities, New Work & Learning, Food & Retail sectors. Partners include AXA, Stadt Zürich, Coop, la Mobilière, MSD, PostFinance, Swisscom, Sanitas, Romande Energie, CSEM, ETH Zürich.
• Therme ZurzachcoreStrategic or Co-development Partner · 22 October 2024Innovative partnership combining Therme Zurzach's spa and wellness expertise with Genknowme's cutting-edge epigenetic solutions. Offers tailor-made wellness and health promotion services integrating epigenetic analyses to design personalized wellness programs, helping customers improve overall health and reduce chronic disease risk linked to nutrition, sedentary lifestyle, addictions, and chronic stress.
• Clinique La PrairiecoreStrategic or Co-development Partner · 1 February 2021Exclusive partnership to provide Genknowme's epigenetic tests to Clinique La Prairie's clients. The test measuring chronic stress impact on health was launched specifically for integration into Clinique La Prairie's Revitalization and Master Detox programs, adding a measure of environment and lifestyle influence on gene expression.
• UnisantécoreStrategic or Co-development Partner · 19 January 2021Research collaboration to explore impacts of lifestyle on epigenetics. Project aims to expand tests to customers from different ethnicities, enlarge scope with chronic stress and sleep quality assessment, and consolidate current product by demonstrating epigenetic variation dynamics after smoking cessation. Funded by Innosuisse.
• Swiss Center for Preventive Medicine / Hôpital de la TourminorStrategic or Co-development Partner · 19 November 2020First partnership to measure epigenetic biological age for personalized preventive medicine. Medical center associated with Hôpital de la Tour (Geneva) became the first to offer Genknowme's epigenetic profile.
• CHUV (Lausanne University Hospital)coreStrategic or Co-development PartnerLong-standing scientific collaboration with CHUV, one of the world's best university hospitals (ranked by Newsweek). Collaborations on research projects and validation of epigenetic tests.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• GlycanAge: GlycanAge sells a biological age test based on glycan biomarkers, targeting health-conscious consumers and clinicians. It competes with Genknowme for the same preventive medicine and longevity positioning, though it uses a different biomarker modality.
• TallyHealth: TallyHealth offers the TallyAge epigenetic age test directly to consumers and through clinicians, positioning in the same longevity/preventive medicine market as Genknowme with overlapping target customers in wellness-oriented practices.
• TruDiagnostic: TruDiagnostic provides commercial epigenetic age testing and multi-omic biomarker services using Illumina methylation arrays, closely mirroring Genknowme's biological age and methylation-based laboratory offering while operating at greater scale in the US.
• Elysium Health (Elysium Index): Elysium Health offers the Elysium Index, a direct-to-consumer epigenetic biological age test that uses DNA methylation analysis. It is a direct peer to Genknowme in the epigenetic age testing category, competing for the same longevity-oriented consumer and clinician demand.
• Muhdo Health: Muhdo provides epigenetic age and wellness testing kits with clinician and consumer channels, competing with Genknowme in the epigenetic biological age testing category across European markets.

Emerging players

• NOVOS: NOVOS offers longevity-focused epigenetic testing alongside its supplement line, targeting a similar health-conscious longevity consumer base that Genknowme serves through physician channels.
• Clockwork (by Function Health): Function Health's Clockwork offering delivers epigenetic age testing as part of a broader preventive health platform, overlapping with Genknowme's biological age offering while bundling additional diagnostics.

Broad incumbents

• Illumina: Illumina manufactures the Infinium MethylationEPIC BeadChips and iScan systems that Genknowme's laboratory workflow depends on. As the dominant incumbent in genomic/epigenetic analysis platforms, it is a key technology provider and strategic dependency.

Regional players

• Buchinger Wilhelmi: Buchinger Wilhelmi is a European fasting and longevity clinic that has collaborated with Genknowme on epigenetic clock research. As an existing partner it represents a comparable regional player channeling epigenetic testing into premium longevity programs.

Others

• Active Motif: Active Motif provides epigenetic research tools and services, including methylation analysis, positioning it as an adjacent service provider and potential partner/competitor to Genknowme's laboratory analysis services business line.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/genknowme

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds7 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genknowme